PharmaTher Holdings Ltd.
PharmaTher Holdings Ltd.
Your view on PHRRF
Overview
What the company does, where it operates, and who runs it.
About PharmaTher Holdings Ltd.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Fabio Chianelli
- Headquarters
- 82 Richmond Street East, Toronto, ON, CA
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Fabio Chianelli
- Headquarters
- 82 Richmond Street East, Toronto, ON, CA
PharmaTher Holdings Ltd., a clinical-stage psychedelics biotech company, focuses on the research, development, and commercialization of novel uses, formulations, and delivery methods of psychedelics to treat mental illness, neurological, and pain disorders.
The company's product in pipeline includes Ketamine intravenous injection, which is in Phase II and III clinical trials for Parkinson's disease, anesthesia and sedation, and amyotrophic lateral sclerosis indications.
Its pipeline also comprises Ketamine Patch that is in Phase I and II clinical trials for treating depression, mental health, complex regional pain syndrome, and pain disorders; and Ketamine Pump, which is in Phase II clinical trial to treat metal health, pain disorders, and surgery/procedure.
In addition, the company engages in the development of PHARMAPATCH, a microneedle patch to deliver psychedelics.
It has collaboration agreements with LTS Lohmann Therapie-Systeme AG for developing Ketamin microneedle patch; Alcami Corporation to develop Ketamin injectables/infusions; BioRAE, Inc. for the development of Ketamin pumps; Revive Therapeutics Ltd. to develop psilocybin microneedle patch; Gesval S.A. for the development of patented continuous-flow process technology for the preparation of ketamine and ketamine analogs; and PharmaTher's to create a proprietary wearable ketamine delivery solution for mental health, neurological and pain disorders.
The company was incorporated in 2019 and is headquartered in Toronto, Canada.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for PharmaTher Holdings Ltd., and the rating behind it. PHRRF last traded at $0.06; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for PharmaTher Holdings Ltd.. Starting points for PharmaTher Holdings Ltd.: EPS -$0.01, beta 2.98 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for PharmaTher Holdings Ltd.. PharmaTher Holdings Ltd. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for PharmaTher Holdings Ltd.. Trailing twelve-month EPS for PharmaTher Holdings Ltd. stands at -$0.01. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for PharmaTher Holdings Ltd.. PharmaTher Holdings Ltd. has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
PharmaTher Holdings Ltd. valued side by side against its closest peers. PharmaTher Holdings Ltd. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold PharmaTher Holdings Ltd., and how their positions are changing. At a $5.3M market value, institutional positions materially move PharmaTher Holdings Ltd.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by PharmaTher Holdings Ltd. executives and directors. Shares of PharmaTher Holdings Ltd. have traded between $0.05 and $0.55 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming PharmaTher Holdings Ltd.. PharmaTher Holdings Ltd. is a $5.3M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming PharmaTher Holdings Ltd.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for PharmaTher Holdings Ltd.. Coverage tracks PharmaTher Holdings Ltd. within Biotechnology (Healthcare). Press releases and market coverage, newest first.